The Origin Fund
How Syngenis channels investment capital into RNA and DNA therapeutic programs.
The Syngenis Origin Fund is a structured investment vehicle designed to fund early-stage RNA and DNA therapeutic programs while keeping early-stage risk off the Syngenis balance sheet. It is managed by independently licensed fund managers operating within a regulated Australian financial services framework.
Four Step Model.
Step 1 — Off-Balance-Sheet Research
Each therapeutic program is funded through a Special Purpose Vehicle (SPV). The SPV operates independently, allowing multiple research programs to run simultaneously while keeping early-stage risk separate from the Syngenis balance sheet.
Step 2 — Inventor Alignment
The scientists and researchers who develop each program hold direct equity in their SPV. This is not a grant or a consulting fee — it is ownership. Inventors remain actively engaged because their financial return is tied directly to the outcome of what they create.
Step 3 — Syngenis Revenue from Every Program
Regardless of who owns the SPV, every program uses Syngenis manufacturing, quality systems, and IP services. Syngenis earns revenue from every program it hosts — building a diversified commercial revenue stream that scales with the size of the portfolio.
Step 4 — Syngenis Acquisition Option
Syngenis retains a contractual option to acquire successful SPVs by issuing shares. When an SPV program produces validated IP or clinical results, Syngenis can bring it back onto the balance sheet at the right time — capturing the upside without carrying the downside risk of early-stage development.
The first Origin Fund is targeting close in Q1 FY27.
For fund information, accredited investor enquiries, or fund manager expressions of interest, contact us.
Ready to work with an integrated life sciences company?
Talk to our team about your program, from candidate design to trial ready material.